Management of limited stage Hodgkin lymphoma
Canadian Hematology Today · 2023
DOI: 10.58931/cht.2023.2123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2023. Verfasst von Shruthi Kodad. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by malignant lymphocytes, known as Reed-Sternberg cells, on a background of non-neoplastic inflammatory cells. Lugano staging determines the stage of Hodgkin lymphoma, which, in turn, determines the treatment and prognosis. Limited-stage disease is defined as Stage I and Stage II, which is diagnosed in more than 50% of patients. Pre-treatment risk stratification, PET-adapted therapy, and combined modality treatment have significantly improved cure rates, making limited-stage HL one of the most curable malignancies. In this article, we discuss the current approach to managing limited-stage HL.
Zitieren
APA
Kodad, S. (2023). Management of limited stage Hodgkin lymphoma. Canadian Hematology Today. https://doi.org/10.58931/cht.2023.2123
Vancouver
Kodad S. Management of limited stage Hodgkin lymphoma. Canadian Hematology Today. 2023. doi:10.58931/cht.2023.2123
BibTeX
@article{Kodad2023,
author = {Kodad, Shruthi},
title = {Management of limited stage Hodgkin lymphoma},
journal = {Canadian Hematology Today},
year = {2023},
doi = {10.58931/cht.2023.2123}
}
EUVIMED